Company Description:

TIM-3 based Bispecific ADC (Antibody-Drug Conjugate) is an emerging therapeutic approach in cancer immunotherapy, leveraging the unique properties of TIM-3 (T-cell immunoglobulin and mucin-domain containing-3) to enhance targeted treatment. By combining a bispecific antibody targeting both TIM-3 and a tumor-associated antigen, this strategy holds the potential to overcome resistance mechanisms often observed with conventional monoclonal antibody therapies. The TIM-3 based Bispecific ADC not only strengthens immune cell engagement but also directs potent cytotoxic payloads directly to cancer cells, minimizing damage to healthy tissues and improving treatment outcomes for patients with various malignancies, including solid tumors and hematologic cancers.